Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment

Introduction COVID-19-associated coagulopathy (CAC) is a well-recognized hematologic complication among patients with severe COVID-19 disease, where macro- and micro-thrombosis can lead to multiorgan injury and failure. Major societal guidelines that have published on the management of CAC are based on consensus of expert opinion, with the current evidence available. As a result of limited studies, there are many clinical scenarios that are yet to be addressed, with expert opinion varying on a number of important clinical issues regarding CAC management. Methods In this review, we utilize current societal guidelines to provide a framework for practitioners in managing their patients with CAC. We have also provided three clinical scenarios that implement important principles of anticoagulation in patients with COVID-19. Conclusion Overall, decisions should be made on acase by cases basis and based on the providers understanding of each patient's medical history, clinical course and perceived risk.

Automated summary

COVID-19-associated coagulopathy (CAC) is a recognized hematologic complication in severe COVID-19 patients, where thrombosis can cause multiorgan injury. Guidelines for managing CAC are based on expert consensus and current evidence, but there are still many clinical scenarios with varying expert opinions.